This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n16http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00156/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00156
rdf:type
n3:Drug
n3:description
An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins. [PubChem]
n3:group
approved nutraceutical
n3:indication
L-Threonine makes up collagen, elastin, and enamel protein. It aids proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation.
owl:sameAs
n16:DB00156 n20:DB00156
dcterms:title
L-Threonine
adms:identifier
n7:DB00156 n8:16857 n9:THR n10:PA451673 n11:C00188 n12:D00041 n18:L-Threonine
n3:mechanismOfAction
L-Threonine is a precursor to the amino acids glycine and serine. It acts as a lipotropic in controlling fat build-up in the liver. May help combat mental illness and may be very useful in indigestion and intestinal malfunctions. Also, threonine prevents excessive liver fat. Nutrients are more readily absorbed when threonine is present.
n3:packager
n5:271B4D21-363D-11E5-9242-09173F13E4C5 n5:271B4D1F-363D-11E5-9242-09173F13E4C5 n5:271B4D20-363D-11E5-9242-09173F13E4C5 n5:271B4D1E-363D-11E5-9242-09173F13E4C5
n3:synonym
L-alpha-amino-beta-hydroxybutyric acid L-2-Amino-3-hydroxybutyric acid L-α-amino-β-hydroxybutyric acid (2S)-threonine (2S,3R)-(-)-Threonine Threonine L-Threonin 2-Amino-3-hydroxybutyric acid L-(-)-Threonine Thr
n3:synthesisReference
Masato Terasawa, Yukie Satoo, Hideaki Yukawa, "Method for production of l-threonine." U.S. Patent US5019503, issued June, 1967.
n13:hasConcept
n14:M0021415
n3:IUPAC-Name
n4:271B4D27-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4D2D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4D2C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4D29-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4D2A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4D2B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4D3D-363D-11E5-9242-09173F13E4C5 n4:271B4D25-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4D26-363D-11E5-9242-09173F13E4C5 n4:271B4D3F-363D-11E5-9242-09173F13E4C5 n4:271B4D23-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4D24-363D-11E5-9242-09173F13E4C5 n4:271B4D40-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4D41-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4D33-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4D34-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4D2E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4D2F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4D31-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4D30-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4D32-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
72-19-5
n3:category
n3:containedIn
n17:271B4D22-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4D39-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4D3B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4D3C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4D3E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4D38-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4D37-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4D3A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4D28-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4D35-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4D36-363D-11E5-9242-09173F13E4C5